Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | Tom Wetherald and Eddie ReillyMinot Light Capital Partners | ImmuCell Corporation $ICCC• NASDAQ | BiotechnologyBiotechnology | Long ICCC (ImmuCell Corporation) ImmuCell is a $65mm market cap animal health company whose core franchise is the First Defense line of products, which protect newborn calves against scours, a leading cause of death for young calves. | BULL | View Pitch → |
| Aug 1, 2026 | Fund Letter | Sean KirkwoodSRK Capital | ImmuCell Corporation $ICCC• NASDAQ | BiotechnologyBiotechnology | Long ICCC (ImmuCell Corporation) ImmuCell Corporation ($ICCC) is an animal health company focused on developing and commercializing preventative biological products, led by its flagship First Defense franchise that treats calf scours (severe neonatal diarrhea in dairy and beef calves). The manager's bullish... | BULL | View Pitch → |
| Jan 27, 2026 | Fund Letter | The London Company of Virginia, LLCThe London Company Small Cap | Application SoftwareSoftware | The London Company Small Cap 2025 Q4 (CCC) CCC operates a vertically integrated, mission-critical software platform for the automotive insurance ecosystem. CCC commands a... | BULL | View Pitch → | |
| Jan 8, 2026 | Fund Letter | Sean KirkwoodSRK Capital | ImmuCell Corporation $ICCC• NASDAQ | BiotechnologyBiotechnology | SRK Capital 2025 Q2 (ICCC) ImmuCell's thesis remains intact following record first quarter results. The highlight of... | BULL | View Pitch → |
| Sep 20, 2025 | Substack | Substack | ImmuCell Corporation $ICCC• NASDAQ | BiotechnologyBiotechnology | A Microcap with 48% Market Share and a Update for the SubstackImmuCell Corporation - ICCC ImmuCell Corporation is positioned for growth with its innovative product, First Defense, which protects calves from major pathogens, and its upcoming product, Re-Tain, which addresses subclinical mastitis in dairy cows. The company has... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.